目的 探讨癫痫平片联合拉莫三嗪治疗癫痫的临床疗效。方法 选取2015年3月-2018年3月在咸阳市中心医院进行治疗的94例癫痫患者为研究对象，根据用药的差别分为对照组（47例）和治疗组（47例）。对照组口服拉莫三嗪片，初始剂量25 mg/次，1次/d，连服2周，随后50 mg/次，1次/d，连服2周，此后，每1~2周增加剂量，最大增加量为50~100 mg，直至达到最佳疗效，之后以100~200 mg/d剂量维持治疗，1次/d。治疗组在对照组治疗基础上口服癫痫平片，1.8 g/次，2次/d。两组均连续治疗12周。观察两组的临床疗效，比较两组治疗前后相关评分、癫痫发作次数和血清学指标的变化情况。结果 治疗后，对照组和治疗组的总有效率分别为80.85%、95.74%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组SES评分、HAD评分、癫痫发作次数、痫样放电、累及导联数治疗前均显著降低，但MoCA评分显著升高，同组治疗前后比较差异有统计学意义（P<0.05）；治疗后，治疗组SES评分、HAD评分、癫痫发作次数、痫样放电、累及导联数显著低于对照组，但MoCA评分显著高于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组白细胞介素-1β（IL-1β）、高迁移率族蛋白1（HMGB1）、同型半胱氨酸（Hcy）、Bcl-2相关X蛋白（Bax）较治疗前均显著降低，但B淋巴细胞瘤-2（Bcl-2）水平升高，同组治疗前后比较差异有统计学意义（P<0.05）；治疗后，治疗组IL-1β、HMGB1、Hcy、Bax水平低于对照组，但Bcl-2水平高于对照组，两组比较差异具有统计学意义（P<0.05）。结论 癫痫平片联合拉莫三嗪治疗癫痫具有较好的临床疗效，能较好地控制癫痫发作，降低机体炎症反应和神经细胞损伤，改善患者焦虑、抑郁状态和认知功能，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Dianxianping Tablets combined with lamotrigine in treatment of epilepsy. Methods Patients (94 cases) with epilepsy in Xianyang Central Hospital from March 2015 to March 2018 were divided into control (47 cases) and treatment (47 cases) groups according to the difference of treatment. Patients in the control group were po administered with Lamotrigine Tablets, initial dosage was 25 mg/time, once daily, and the drug was administered for two weeks; then 50 mg/time, once daily for two weeks. After that, the dosage was increased every 1 to 2 weeks, and the maximum incremental dosage was 50 to 100 mg until the optimal effect was achieved, and then maintained with the dosage of 100 to 200 mg/d, once daily. Patients in the treatment group were po administered with Dianxianping Tablets on the basis of the control group, 1.8 g/time, twice daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacy was evaluated, and the changes of related scores, seizures number and serological indicators in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment group were 80.85% and 95.74%, and there were differences between two groups (P<0.05).After treatment, SES score, HAD score, epileptic seizures numbers, epileptic discharge, and involved leads numbers were significantly decreased in two groups, but MoCA score was significantly increased, and there were differences in the same group (P<0.05). After treatment, SES score, HAD score, epileptic seizures numbers, epileptic discharge, and involved leads numbers in the treatment group were lower than those in the control group, but MoCA score was higher than that in the control group, and there were differences between two groups (P<0.05). After treatment, IL-1β, HMGB1, Hcy, and Bax were significantly decreased in two groups, but Bcl-2 was significantly increased, and there were differences in the same group (P<0.05). After treatment, IL-1β, HMGB1, Hcy, and Bax in the treatment group were lower than those in the control group, but Bcl-2 was higher than that in the control group, and there were differences between two groups (P<0.05). Conclusion Dianxianping Tablet combined with lamotrigine has significant clinical effect in treatment of epilepsy, and can control epileptic seizure, also can reduce inflammatory response and nerve cell injury, and improve anxiety, depression and cognitive function, which has a certain clinical application value.